Absence of Renal and Hepatic Toxicity After Four Hours of 1.25 Minimum Alveolar Anesthetic Concentration Sevoflurane Anesthesia in Volunteers

Sevoflurane is degraded by CO2 absorbents to Compound A.The delivery of sevoflurane with a low fresh gas flow increases the generation of Compound A. The administration of Compound A to rats can produce injury to renal tubules that is dependent on both the dose and duration of exposure to Compound A. The present study evaluated renal and hepatic function in eight volunteers after a 1-L/min delivery of 3% (1.25 minimum alveolar anesthetic concentration) sevoflurane for 4 h. Volunteers gave their informed consent and provided 24-h urine collections before and for 3 days after sevoflurane anesthesia. Urine samples were analyzed for glucose, protein, albumin, and alpha- and pi-glutathione-S-transferase. Daily blood samples were analyzed for markers of renal and liver injury or dysfunction. Circuit Compound A and plasma fluoride concentrations were determined. During anesthesia, the average maximal inspired Compound A concentration was 39 +/- 6 (mean +/- SD). The median mean arterial pressure, esophageal temperature, and end-tidal CO2 were 62 +/- 6 mm Hg, 36.5 +/- 0.3[degree sign]C, and 30.5 +/- 0.5 mm Hg, respectively. Two hours after anesthesia, the plasma fluoride concentration was 50 +/- 9 [micro sign]mol/L. All markers of hepatic and renal function were unchanged after anesthesia (repeated-measures analysis of variance P > 0.05). Low-flow sevoflurane was not associated with renal or hepatic injury in humans based on unchanged biochemical markers of renal and liver function. Implications: Sevoflurane delivered in a 3% concentration with a fresh gas flow of 1 L/min for 4 h generated an average maximal Compound A concentration of 39 ppm but did not result in any significant increase in sensitive markers of renal function or injury, including urinary protein, albumin, glucose, and alpha- and pi-glutathione-S-transferase. (Anesth Analg 1998;86:662-7)

[1]  R. Weiskopf,et al.  Dose-Related Biochemical Markers of Renal Injury After Sevoflurane Versus Desflurane Anesthesia in Volunteers , 1997, Anesthesia and analgesia.

[2]  A. Artru,et al.  Assessment of Low‐flow Sevoflurane and Isoflurane Effects on Renal Function Using Sensitive Markers of Tubular Toxicity , 1997, Anesthesiology.

[3]  K. Ikeda,et al.  Effects of Low‐flow Sevoflurane Anesthesia on Renal Function: Comparison with High‐flow Sevoflurane Anesthesia and Low‐flow Isoflurane Anesthesia , 1997, Anesthesiology.

[4]  R. Jamison,et al.  Low-flow (1 l/min) sevoflurane: is it safe? , 1997, Anesthesiology.

[5]  R. Weiskopf,et al.  Nephrotoxicity of Sevoflurane Versus Desflurane Anesthesia in Volunteers , 1997, Anesthesia and analgesia.

[6]  E. Kharasch,et al.  Role of Renal Cysteine Conjugate beta‐Lyase in the Mechanism of Compound A Nephrotoxicity in Rats , 1997, Anesthesiology.

[7]  J. G. Kenna,et al.  Sevoflurane degradation by soda lime in a circle breathing system , 1996, Anaesthesia.

[8]  E. Eger,et al.  Factors Affecting Production of Compound A from the Interaction of Sevoflurane with Baralyme Registered Trademark and Soda Lime , 1996, Anesthesia and analgesia.

[9]  E. Eger,et al.  The safety of sevoflurane has not been adequately established. , 1996, Anesthesia and analgesia.

[10]  K. Ikeda,et al.  Renal and Hepatic Function in Surgical Patients After Low-Flow Sevoflurane or Isoflurane Anesthesia , 1996, Anesthesia and analgesia.

[11]  P. Prokocimer,et al.  Inhalation Toxicity Study of a Haloalkene Degradant of Sevoflurane, Compound A (PIFE), in Sprague‐Dawley Rats , 1995, Anesthesiology.

[12]  T. Baillie,et al.  Nephrotoxicity of sevoflurane compound A [fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether] in rats: evidence for glutathione and cysteine conjugate formation and the role of renal cysteine conjugate beta-lyase. , 1995, Biochemical and biophysical research communications.

[13]  K. Ikeda,et al.  Long‐duration, Low‐flow Sevoflurane Anesthesia Using Two Carbon Dioxide Absorbents: Quantification of Degradation Products in the Circuit , 1994, Anesthesiology.

[14]  E. Eger,et al.  Toxicity of Compound A in Rats: Effect of Increasing Duration of Administration , 1994, Anesthesiology.

[15]  K. Ikeda,et al.  Closed‐circuit Anesthesia with Sevoflurane in Humans Effects on Renal and Hepatic Function and Concentrations of Breakdown Products with Soda Lime in the Circuit , 1994, Anesthesiology.

[16]  M. Malcomson,et al.  Quantification of the degradation products of sevoflurane in two CO2 absorbants during low-flow anesthesia in surgical patients. , 1992, Anesthesiology.